Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.65 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694561 | 0.83 | NOTUM (0.78) | NOTUMLMNAHTTHPGDTLR8 | |
| SCHEMBL31675268 | 0.83 | NOTUM (0.46) | NOTUMNPBWR1LMNAHTTHPGD | |
| Ethoxycarbonyl Group SCHEMBL28826450 | 0.82 | NOTUM (0.47) | NOTUMNPBWR1LMNAHTTHPGD | |
| SCHEMBL2610163 | 0.81 | NOTUM (0.75) | NOTUMLMNAHTTHPGDTLR8 | |
| SCHEMBL614454 | 0.81 | NOTUM (0.63) | NOTUMNPBWR1LMNAHTTHPGD | |
| SCHEMBL28268977 | 0.79 | NOTUM (0.61) | NOTUMNPBWR1LMNAHTTHPGD | |
| SCHEMBL6408779 | 0.79 | NOTUM (1.00) | NOTUMNPBWR1HTT | |
| Benzene SCHEMBL27815360 | 0.78 | NOTUM (0.63) | NOTUMLMNAHTTHPGDTLR8 | |
| SCHEMBL14814390 | 0.78 | NOTUM (1.00) | NOTUMLMNAHTTHPGDTLR8 | |
| SCHEMBL29376264 | 0.77 | TLR8 (0.58) | NOTUMLMNAHTTHPGDTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161335-A | Azole derivative containing double bond structure and application thereof | 沈阳药科大学 | 2024-12-20 | — | — | CN | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| CN-116751174-A | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-107056727-B | 2-aryl-5-arylseleno-1, 3, 4-oxadiazole compound and preparation method thereof | 温州医科大学 | 2020-12-11 | — | — | CN | disclosed |
| CN-104936963-B | Sulfide derivative as kinases inhibitor | 普罗齐纳斯有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107056727-A | A kind of oxadiazole compound of 5 arylseleno of 2 aryl 1,3,4 and preparation method | 温州医科大学 | 2017-08-18 | — | — | CN | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004014882-A2 | PROTEASOME INHIBITORS : PEPTIDE DERIVATIVES HAVING C-TERMINAL HETEROARYL GROUPS | AXYS PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6605631-B1 | Controlling fungi and pests; improved activity and plant tolerability | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-12 | — | — | US | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885NPBWR1 1831/4885LMNA 2507/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885NPBWR1 811/4885LMNA 1919/4885 |
| US-20070112045-A1 | Triazole ppar modulators | PPARD, PPARA, PPARG | NOTUM 1060/4885NPBWR1 305/4885LMNA 3550/4885 |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | NOTUM 1001/4885NPBWR1 2553/4885LMNA 736/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | NOTUM 4288/4885NPBWR1 576/4885LMNA 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.